Quanta Therapeutics is a biotechnology startup founded in 2018, specializing in the development of novel therapeutics for conformational blockade of RAS in cancer. The company recently secured a significant $50.70M Series D investment on 22 May 2023. The investment was led by a consortium of prominent investors including Longitude Capital, Sofinnova Investments, AbbVie Ventures, Vida Ventures, WS Investment Company, Avidity Partners, GC&H Investments, Biotechnology Value Fund, and Surveyor Capital.
Quanta Therapeutics operates within the Biotechnology, Health Care, Health and Wellness, and Medical Devices industries, demonstrating a wide-reaching impact potential. With this latest round of funding, the company is well-positioned to advance its pioneering research and drive innovation in the field of cancer therapeutics. This investment not only serves as a testament to the confidence investors have in Quanta Therapeutics' vision and capabilities but also underscores the growing interest in biotechnology ventures focused on addressing critical unmet medical needs.
